Pliant Therapeutics (PLRX) Stock Price, News & Analysis

Company Overview

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key Stats

• Today's Range: $12.45 to $13.17
• 50-Day Range: $11.84 to $14.35
• 52-Week Range: $10.29 to $19.62
• Volume: 80,858 shs
• Average Volume: 457,705 shs
• Market Capitalization: $775.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.57
• Consensus Rating: Buy

Pliant Therapeutics Stock Analysis - MarketRank™

Pliant Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 101st out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Pliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pliant Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.71) to ($4.03) per share.

Price to Book Value per Share Ratio

Pliant Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.06% of the outstanding shares of Pliant Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Pliant Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Pliant Therapeutics has recently decreased by 0.14%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pliant Therapeutics does not currently pay a dividend.

Dividend Growth

Pliant Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.73

Percentage of Shares Shorted

12.06% of the outstanding shares of Pliant Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Pliant Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Pliant Therapeutics has recently decreased by 0.14%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.68

News Sentiment

Pliant Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pliant Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $804,530.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Pliant Therapeutics is held by insiders.

Percentage Held by Institutions

97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PLRX Stock Analysis - Frequently Asked Questions

How have PLRX shares performed this year?

Pliant Therapeutics' stock was trading at $18.11 at the beginning of the year. Since then, PLRX shares have decreased by 29.0% and is now trading at $12.86.
View the best growth stocks for 2024 here.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.07.

When did Pliant Therapeutics IPO?

Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' top institutional shareholders include First Light Asset Management LLC (5.59%), Great Point Partners LLC (4.34%), Candriam S.C.A. (1.38%) and Dimensional Fund Advisors LP (0.51%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull and Mike Ouimette.
View institutional ownership trends.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT) and Archer-Daniels-Midland (ADM).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 9/19/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PLRX
• CUSIP: N/A
• CIK: 1746473
• Web: pliantrx.com
• Phone: 650-481-6770
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $40.57
• High Stock Price Target: $45.00
• Low Stock Price Target: $33.00
• Potential Upside/Downside: +220.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-161,340,000.00
• Net Margins: N/A
• Pretax Margin: -68,847.98%
• Return on Equity: -41.05%
• Return on Assets: -36.04%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 14.47
• Quick Ratio: 14.47

Sales & Book Value

• Annual Sales: $1.58 million
• Price / Sales: 487.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.91 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 60,800,000
• Free Float: 56,465,000
• Market Cap: $770.94 million
• Optionable: Optionable
• Beta: 1.14